Derfor skal en tæt monitorering af glykæmisk kontrol, dosisjustering inden for den anbefalede dosering og ændringer i diabetesbehandlingen overvejes ved samtidig indgivelse af kationiske lægemidler, der elimineres via tubulær sekretion i nyrerne.
Therefore, close monitoring of glycaemic control, dose adjustment within the recommended posology and changes in diabetic treatment should be considered when cationic drugs that are eliminated by renal tubular secretion are co-administered.